Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

PRHSX vs. ETHSX: which is better?

Bottom line

PRHSX vs ETHSX: the short answer

PRHSX (T. Rowe Price Health Sciences Fund, Inc.) and ETHSX (Eaton Vance Worldwide Health Sciences Fund) share a meaningful slice of their top holdings — about 64% by weight.

But PRHSX is far broader, holding 279 positions to 42 for ETHSX, so beyond the top names it adds exposure ETHSX doesn't have.

PRHSX is cheaper at 0.83% vs 1.18% — a difference of $35 a year per $10,000 invested.

Over five years, ETHSX returned +5.3% a year vs +4.2% for PRHSX (reporting dates differ).

ETHSX has a front-end sales load of up to 5.25%; the other does not.

Updated Nov 19, 2026

PRHSX vs ETHSX side by side

PRHSXETHSX
TypeMutual fundMutual fund
Fund familyT. Rowe PriceMorgan Stanley
CategoryHealth Care SectorHealth Care Sector
Expense ratio0.83%1.18%
Annual cost per $10k$83$118
10-yr cost on $10k (prospectus)$1,025$1,911
Max front load—5.25%
12b-1 fee—0.25%
1-yr return+17.7%−1.9%
5-yr return (annualized)+4.2%+5.3%
10-yr return (annualized)+9.1%+6.4%
Best quarter+23.5%+14.2%
Worst quarter−15.8%−12.1%
Net assets (fund)$11.9B$757.9M
Number of holdings27942
Portfolio turnover62%3%
Returns as ofDec 31, 2025Dec 31, 2024

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearPRHSXETHSXDifference
2024+1.8%+3.5%−1.7%
2023+3.1%+5.7%−2.6%
2022−12.2%−9.4%−2.8%
2021+13.3%+22.1%−8.8%
2020+30.1%+13.0%+17.1%
2019+29.1%+26.0%+3.1%
2018+1.2%+6.0%−4.8%
2017+28.0%+16.2%+11.7%
2016−10.4%−14.9%+4.5%

Source: Fund prospectus bar charts

Holdings overlap

12 of PRHSX's top 25 holdings also appear in ETHSX's top 25.

Shared top holdings
HoldingPRHSXETHSX
Eli Lilly & Co14.28%12.47%
Johnson & Johnson6.63%6.45%
Unitedhealth Group Inc5.99%5.49%
Abbvie Inc5.10%6.46%
Merck & Co. Inc.4.01%5.08%
Gilead Sciences Inc2.82%3.34%
Thermo Fisher Scientific Inc2.52%2.79%
Vertex Pharmaceuticals Inc2.28%3.38%
Bristol-myers Squibb Co2.11%4.25%
Abbott Laboratories1.89%1.65%
Intuitive Surgical Inc1.87%2.72%
Stryker Corp1.78%2.21%

Source: SEC Form N-PORT

PRHSX top 10

  1. Eli Lilly & Co — 14.28%
  2. Johnson & Johnson — 6.63%
  3. Unitedhealth Group Inc — 5.99%
  4. Abbvie Inc — 5.10%
  5. Merck & Co. Inc. — 4.01%
  6. Gilead Sciences Inc — 2.82%
  7. Thermo Fisher Scientific Inc — 2.52%
  8. Vertex Pharmaceuticals Inc — 2.28%
  9. Bristol-myers Squibb Co — 2.11%
  10. Abbott Laboratories — 1.89%

ETHSX top 10

  1. Eli Lilly & Co — 12.47%
  2. AbbVie Inc — 6.46%
  3. Johnson & Johnson — 6.45%
  4. AstraZeneca PLC — 6.24%
  5. UnitedHealth Group Inc — 5.49%
  6. Roche Holding AG — 5.44%
  7. Merck & Co Inc — 5.08%
  8. Bristol-Myers Squibb Co — 4.25%
  9. Vertex Pharmaceuticals Inc — 3.38%
  10. Gilead Sciences Inc — 3.34%

FAQ

What is the difference between PRHSX and ETHSX?
PRHSX (T. Rowe Price Health Sciences Fund, Inc.) and ETHSX (Eaton Vance Worldwide Health Sciences Fund) share a meaningful slice of their top holdings — about 64% by weight. But PRHSX is far broader, holding 279 positions to 42 for ETHSX, so beyond the top names it adds exposure ETHSX doesn't have.
Which is cheaper, PRHSX or ETHSX?
PRHSX has the lower expense ratio (0.83%).
Should I own both PRHSX and ETHSX?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.